Cart
sales@molnova.com
Xipamide
CAS No. 14293-44-8
Xipamide( Diurexan | Aquaphor )
Catalog No. M26867 CAS No. 14293-44-8
Xipamide is a sulfonamide-based diuretic with antihypertensive properties. Xipamide selectively inhibits anion exchanger.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 31 | In Stock |
|
| 25MG | 59 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameXipamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionXipamide is a sulfonamide-based diuretic with antihypertensive properties. Xipamide selectively inhibits anion exchanger.
-
DescriptionXipamide is a sulfonamide-based diuretic with antihypertensive properties. Xipamide selectively inhibits anion exchanger.
-
In Vitro——
-
In Vivo——
-
SynonymsDiurexan | Aquaphor
-
PathwayOthers
-
TargetOther Targets
-
RecptorCB1| GABAB
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number14293-44-8
-
Formula Weight354.81
-
Molecular FormulaC15H15ClN2O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (704.60 mM)
-
SMILESCc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Francesca Ferlenghi, et al. The GABA B receptor positive allosteric modulator COR659: In vitro metabolism, in vivo pharmacokinetics in rats, synthesis and pharmacological characterization of metabolically protected derivatives. Eur J Pharm Sci. 2020 Dec 1;155:105544.
molnova catalog
related products
-
GSK-3 inhibitor 3
GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively.
-
Demethylzeylasteral
Demethylzeylasteral has strong immunosuppressive activity, can be used in the fields of organ transplantation and autoimmune disorders.
-
Inebilizumab
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells.
